{"type":"trials","record":{"id":41674,"source_id":"clinicaltrials-gov","external_id":"NCT04101877","title":"The Sahlgrenska Anti-VEGF Study","brief_summary":"The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Vastra Gotaland Region","enrollment":402,"countries":["Sweden"],"start_date":"2020-09-03","completion_date":"2027-05-01","last_update_date":"2025-11-21","source_url":"https://clinicaltrials.gov/study/NCT04101877","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"SAHLVE","age_range":"50 Years","comparator":"Eylea","organization":"Vastra Gotaland Region","interventions":["Bevacizumab Injection","Aflibercept Injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of injections — Two years","Best-corrected visual acuity (BCVA), distance — Two years","Best-corrected visual acuity (BCVA), near — Two years","Macular thickness (Central Retinal Thickness; CRT) — Two years","Intraocular pressure (IOP) — Two years","Recurrence interval — Two years","Durability — Two years","Cost efficiency — Two years","Vision-related quality of life — Two years","Cost-benefit — Two years"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Bevacizumab Injection","Aflibercept Injection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04101877","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-09-03 to 2027-05-01","comparator":"Eylea","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.851Z","intervention":["Bevacizumab Injection","Aflibercept Injection"],"participants":402,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of injections — Two years","Best-corrected visual acuity (BCVA), distance — Two years","Best-corrected visual acuity (BCVA), near — Two years","Macular thickness (Central Retinal Thickness; CRT) — Two years","Intraocular pressure (IOP) — Two years","Recurrence interval — Two years","Durability — Two years","Cost efficiency — Two years","Vision-related quality of life — Two years","Cost-benefit — Two years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41674","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}